NU7441 (KU-57788)

Catalog No.S2638

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.

Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

NU7441 (KU-57788) Chemical Structure

NU7441 (KU-57788) Chemical Structure
Molecular Weight: 413.49

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

NU7441 (KU-57788) is available in the following compound libraries:

DNA-PK Inhibitors with Unique Features

  • Non-specific DNA-PK Inhibitor

    PI-103 DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.

  • Most Potent DNA-PK Inhibitor

    PIK-75 DNA-PK, IC50=2 nM.

  • Newest DNA-PK Inhibitor

    KU-0060648 Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

  • Classic DNA-PK Inhibitor

    NU7026 Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Product Information

  • Compare DNA-PK Inhibitors
    Compare DNA-PK Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.
Targets DNA-PK [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
PI3K [1]
(Cell-free assay)
ATM [1]
(Cell-free assay)
ATR [1]
(Cell-free assay)
IC50 14 nM 1.7 μM 5 μM >100 μM >100 μM
In vitro NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. [2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. [3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. [4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. [5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H1770NIXEWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTBwMEKxOFMh|ryPNEfTO2hUSU6JRWK=
A172NHXs[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvOZ5JKSzVyPUCuNVU{OTZizszNNXP6PJBwW0GQR1XS
NCI-H526NXLGTlNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzNTWM2OD1yLkK4OFA4KM7:TR?=NYjlNIF5W0GQR1XS
HDLM-2NIjZb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPhN4hKSzVyPUCuN|I{PDVizszNNFfIZpFUSU6JRWK=
HuO-3N1NYi2W|hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHCTWM2OD1yLkS2OlM3KM7:TR?=NGrjUZJUSU6JRWK=
NCI-SNU-1M4PNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGSybZNKSzVyPUCuOlA6QTRizszNMWXTRW5ITVJ?
SK-N-ASNGf5enhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHaTWM2OD1yLk[yNlE3KM7:TR?=MUPTRW5ITVJ?
LoVoNEn4fGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7JRodKSzVyPUCuPFY4PDlizszNMlnRV2FPT0WU
LAMA-84MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XpNGlEPTB;MD65PFg{OyEQvF2=NFnmOIxUSU6JRWK=
CTB-1NHjCcVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTFwMUG1OFYh|ryPNXj3VHF5W0GQR1XS
KP-N-YSNWHk[4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjO[5FKSzVyPUGuNVQzOzFizszNMn7TV2FPT0WU
HHMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml:1TWM2OD1zLkG4NFk{KM7:TR?=M4nVcnNCVkeHUh?=
CHL-1NVPiRnU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M164ZWlEPTB;MT6yNVM3QCEQvF2=M2\RUXNCVkeHUh?=
NB7MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTFwMkS3OFUh|ryPNGrvVWVUSU6JRWK=
HL-60MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTFwM{ixPUDPxE1?NE\ubmtUSU6JRWK=
639-VNF7wbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTFwNESxNlgh|ryPMVzTRW5ITVJ?
NCI-H1793Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVX3Zm9kUUN3ME2xMlQ2QDRizszNMVLTRW5ITVJ?
NEC8M{XjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jPXmlEPTB;MT61OVM2KM7:TR?=NX3wVWxuW0GQR1XS
PA-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTFwNUiyPVQh|ryPNXPBTmxIW0GQR1XS
D-423MGNXG1e2lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHn3[HRKSzVyPUGuOlk{PjFizszNNEDVO2RUSU6JRWK=
NCI-H292Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPlTWM2OD1zLke0NFE{KM7:TR?=M4Dv[XNCVkeHUh?=
SK-MEL-1NUjrSG5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\VTWM2OD1zLke5OFc6KM7:TR?=M1L0WnNCVkeHUh?=
LB2241-RCCNWjiXopQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEKxdplKSzVyPUKuNVQyPDZizszNM2m5dnNCVkeHUh?=
SK-MEL-3MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTJwMU[0PUDPxE1?NFXDV5BUSU6JRWK=
MHH-PREB-1M4XpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\wWG9GUUN3ME2yMlE3PjB7IN88US=>M{TzbXNCVkeHUh?=
BFTC-905NFv1fGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rzdWlEPTB;Mj6xOlY5PyEQvF2=M1HqXnNCVkeHUh?=
Ramos-2G6-4C10MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonzTWM2OD1{LkG5PVA6KM7:TR?=NGLNdm5USU6JRWK=
G-361MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\GTWM2OD1{LkKxOlgh|ryPMnSzV2FPT0WU
MOLT-4NFPjc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\UVWlEPTB;Mj6yNVg5QCEQvF2=MYrTRW5ITVJ?
DELMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1m1T2lEPTB;Mj6zOVU3PCEQvF2=NUTyc4ZDW0GQR1XS
MV-4-11MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFznclRKSzVyPUKuN|c{QSEQvF2=NFLtd5JUSU6JRWK=
SK-NEP-1NXe4WG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7OeHZ2UUN3ME2yMlM5Pzh|IN88US=>NH3SUVJUSU6JRWK=
RS4-11NGHHN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\5PWNMUUN3ME2yMlU3ODJ|IN88US=>MofYV2FPT0WU
HuH-7MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjGPYd7UUN3ME2yMlU3PzB{IN88US=>MX3TRW5ITVJ?
A101DNXjnTXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTJwNkGzN|gh|ryPMWPTRW5ITVJ?
KG-1NH;pOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoG0TWM2OD1{Lk[3PVI1KM7:TR?=NWjZOWt{W0GQR1XS
KALS-1M{Lx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\OPWlEPTB;Mj62PVY{OyEQvF2=MVnTRW5ITVJ?
VMRC-RCZNX;afXlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTJwN{ezNlgh|ryPM13XZXNCVkeHUh?=
SK-UT-1M2rIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\oTWM2OD1|LkG1N|Eh|ryPNUHNbFBQW0GQR1XS
SW962NX\NfVlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XZVGlEPTB;Mz6yNFM2OiEQvF2=NIfw[HZUSU6JRWK=
DBTRG-05MGMln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUno[FBjUUN3ME2zMlI5ODh3IN88US=>MUHTRW5ITVJ?
PANC-08-13NVvwfFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV2ySVhbUUN3ME2zMlQyOjd6IN88US=>NV[4NXdIW0GQR1XS
QIMR-WILM1jwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvHdWdKSzVyPUOuOFE{PDFizszNMXnTRW5ITVJ?
SK-MEL-30M2TlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTNwNEK1PVgh|ryPNWL1botiW0GQR1XS
697MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTNwNES5PVMh|ryPM2jGWnNCVkeHUh?=
NYMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojrTWM2OD1|LkS1NFIzKM7:TR?=NXLGfI5pW0GQR1XS
ES7NUn5PYJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\QTWM2OD1|LkS2O|I6KM7:TR?=MYfTRW5ITVJ?
JVM-3NIHlbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XDZ2lEPTB;Mz60PFA4PyEQvF2=NHPYXmRUSU6JRWK=
U031NULQVFk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nL[2lEPTB;Mz61PVM3QCEQvF2=NInjXnZUSU6JRWK=
BHT-101M2jXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoC1TWM2OD1|LkW5PVg2KM7:TR?=MV7TRW5ITVJ?
8305CNFnU[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzDS204UUN3ME2zMlYyPzN4IN88US=>MVnTRW5ITVJ?
MG-63MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTNwNkK2O|Yh|ryPNXLhdo9HW0GQR1XS
NOS-1NFTIVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjVTWM2OD1|Lk[1N|EzKM7:TR?=NWLuXHBzW0GQR1XS
YH-13MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3wTWM2OD1|Lki3NVg6KM7:TR?=MkjFV2FPT0WU
LXF-289M2P6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LzTWlEPTB;Mz65NVA1OSEQvF2=MWTTRW5ITVJ?
GOTONYLOfpE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnEfotvUUN3ME2zMlkyPDlizszNNUG2T4F[W0GQR1XS
EKVXMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTRwMkK1NlQh|ryPNEjRZ|JUSU6JRWK=
CAL-51M17Zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jZfWlEPTB;ND6yOFg2PCEQvF2=NWnCfXhqW0GQR1XS
AN3-CANV3jcGdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\LRlcyUUN3ME20MlI2QDF|IN88US=>Mon2V2FPT0WU
IA-LMMmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWP4TJR1UUN3ME20MlI4QTN3IN88US=>MWTTRW5ITVJ?
KU-19-19NIH5O5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnDVVhPUUN3ME20MlMzQTJzIN88US=>NYflNHhbW0GQR1XS
A704NVTEV4dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnZNW5uUUN3ME20MlQxQDh6IN88US=>M3jEe3NCVkeHUh?=
RH-18Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3CTWM2OD12LkS0PVU{KM7:TR?=M{DudnNCVkeHUh?=
IST-MEL1NEm0PGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILzR4lKSzVyPUSuOVgzPjNizszNMoTTV2FPT0WU
LU-134-AMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXydZFKSzVyPUSuOVk3QDVizszNM1jvUXNCVkeHUh?=
SF126MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nLcWlEPTB;ND62NFcyPSEQvF2=MYXTRW5ITVJ?
EFO-27MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnCdpM3UUN3ME20MlY3PTJ3IN88US=>NVnXUHFlW0GQR1XS
SN12CM1;zeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTRwN{G4PVgh|ryPNF7v[2FUSU6JRWK=
L-363NVHYU3AxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTRwN{exNVYh|ryPMYHTRW5ITVJ?
MEL-HOMmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTRwN{e5PFkh|ryPNUnYOno2W0GQR1XS
TYK-nuNXXOT|gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TIeGlEPTB;ND64NFEzQCEQvF2=M3G0UHNCVkeHUh?=
MDA-MB-415M2PTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXDWmFKSzVyPUWuNFA{OTRizszNNWDwbGFqW0GQR1XS
HCC70NHTmdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4X0OGlEPTB;NT6wN|k{QSEQvF2=MnTIV2FPT0WU
IGROV-1Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTVwMkWyPVIh|ryPNF\rdplUSU6JRWK=
NCI-H1355NHLvSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnrWVVKSzVyPUWuNlk3KM7:TR?=NGfmbIZUSU6JRWK=
23132-87Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFn4TVZKSzVyPUWuN|IxOjRizszNM4Dy[XNCVkeHUh?=
NB69NYHzbmFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXj6Z4lqUUN3ME21MlMzPDJizszNMljZV2FPT0WU
HSC-2NVToRY9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLOTWM2OD13LkSxO|c{KM7:TR?=NWnDUoFFW0GQR1XS
KYSE-410NEPuV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLKOoVKSzVyPUWuOFc3OzZizszNM3jxVXNCVkeHUh?=
GCIYMmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fpNmlEPTB;NT61NVM4QCEQvF2=NH[2SHNUSU6JRWK=
A427MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHpdXlKSzVyPUWuOVM3PjFizszNNHrqcYRUSU6JRWK=
ChaGo-K-1Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTVwNU[1PVkh|ryPM323RnNCVkeHUh?=
PFSK-1NWrJOJFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTVwNkKxPVQh|ryPM3i0OXNCVkeHUh?=
MLMAM2nZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjmOIVKSzVyPUWuPFM3ODZizszNMnziV2FPT0WU
RVH-421M{TUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzENmFKSzVyPU[uNFc{OzhizszNNGK4R|dUSU6JRWK=
LB1047-RCCMlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnj4TWM2OD14LkG3OVIzKM7:TR?=MXrTRW5ITVJ?
MHH-NB-11M2i1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfoTWM2OD14LkOyO|IyKM7:TR?=NUTvToRTW0GQR1XS
J-RT3-T3-5NUHGeHpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLodIFPUUN3ME22MlY{OjlzIN88US=>NHTGNHpUSU6JRWK=
UM-UC-3NILrRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUGwVWZOUUN3ME22MlY1OzN2IN88US=>MXfTRW5ITVJ?
IST-SL1M3rV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVm5[ZBtUUN3ME22MlY6OzZ7IN88US=>M1HNS3NCVkeHUh?=
NB14NVnUc5F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfnTWM2OD14Lke5O|YyKM7:TR?=M3ziT3NCVkeHUh?=
NBsusSRM4nWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TR[2lEPTB;Nj64NlUxOiEQvF2=NVOwWnQ3W0GQR1XS
D-263MGMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDhXo5tUUN3ME22MlkyODZ6IN88US=>MkPOV2FPT0WU
NCI-H2347MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\rS4JKSzVyPU[uPVMzOTNizszNMUTTRW5ITVJ?
ES8NELMXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrKTWM2OD14Lkm3OVg5KM7:TR?=NV\Tc5JQW0GQR1XS
786-0MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\kPWlEPTB;Nz6wPVc5PiEQvF2=M2PTNnNCVkeHUh?=
EPLC-272HMofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHO4T|hKSzVyPUeuNVYzPDZizszNMU\TRW5ITVJ?
CAPAN-1MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTdwMkSzOVkh|ryPNWe2VJpUW0GQR1XS
NCI-H82NEmzVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvtUY9KSzVyPUeuNlY3PTlizszNMormV2FPT0WU
G-402MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTdwM{CwOVEh|ryPNU\sOYpPW0GQR1XS
SW982Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDKTWM2OD15LkOwNlA{KM7:TR?=NIjROYFUSU6JRWK=
OVCAR-4MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnVd3FKSzVyPUeuN|E{OjhizszNM3X4NHNCVkeHUh?=
KARPAS-299NHvzdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzxTWM2OD15LkOyOlIzKM7:TR?=Moj6V2FPT0WU
MIA-PaCa-2MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2m3U2lEPTB;Nz6zOlgzOyEQvF2=NF\BRmZUSU6JRWK=
AU565MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF74dndKSzVyPUeuOVk5OzNizszNM2T0WHNCVkeHUh?=
GAMGNGK3[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vXN2lEPTB;Nz62OFE{OSEQvF2=NIe2XGZUSU6JRWK=
HuO9MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTdwN{G3OFMh|ryPMWnTRW5ITVJ?
ACNMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7RTJJKSzVyPUeuO|Q{OyEQvF2=MYnTRW5ITVJ?
RO82-W-1NVT5fVhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmC0TWM2OD15Lke0OVM{KM7:TR?=M{Lzd3NCVkeHUh?=
NKM-1NFnGVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\uUmVNUUN3ME23Mlc1QTV3IN88US=>MVzTRW5ITVJ?
CAL-12TNXnOV4VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTdwOUSzOVIh|ryPM2fncHNCVkeHUh?=
FADUNFrzXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRThwMEO2OVQh|ryPM3;jNHNCVkeHUh?=
NCI-H28NXrMVI5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HDRmlEPTB;OD6xOlk3OiEQvF2=M3nQXXNCVkeHUh?=
LCLC-97TM1MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PpNGlEPTB;OD6yNVEzOiEQvF2=MWrTRW5ITVJ?
CHP-134Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRThwMkSxPFUh|ryPMlzjV2FPT0WU
HT-1080NVzmSIRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LuRWlEPTB;OD6yOVA6OyEQvF2=NWDqcJVLW0GQR1XS
PC-3NUfGbIp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\EO3B6UUN3ME24MlI4Ozl{IN88US=>MWPTRW5ITVJ?
SNU-449MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnn2TWM2OD16LkK3PVMh|ryPMmnFV2FPT0WU
VA-ES-BJMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3y2ZWlEPTB;OD6zOFY5PiEQvF2=M4nXbXNCVkeHUh?=
HTMon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRThwM{[0PUDPxE1?MUfTRW5ITVJ?
HOSMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrxUGxjUUN3ME24MlM4PTh7IN88US=>MVLTRW5ITVJ?
KNS-62MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF74ZYxKSzVyPUiuN|c4PjJizszNMWTTRW5ITVJ?
OAW-42M4HKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRThwOUW5OlQh|ryPNGTrOW9USU6JRWK=
A549M1PJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTTNJh{UUN3ME25MlA6PjF{IN88US=>Mn7EV2FPT0WU
CAKI-1NV7MR|JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PYRmlEPTB;OT6xOlYyKM7:TR?=NF\tO2JUSU6JRWK=
HCC1937NUfpNI17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTlwNkm4OlUh|ryPMnX4V2FPT0WU
GI-ME-NNVrpSFFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPv[5I6UUN3ME25MlcxOTN5IN88US=>NFfne|lUSU6JRWK=
DU-4475NX\XXoN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrITWM2OD17Lkm2PVM6KM7:TR?=MVLTRW5ITVJ?
EM-2Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXoWVFqUUN3ME2xNE4zPDJ4IN88US=>NYHROJFTW0GQR1XS
NCI-H1755Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWmx[G9GUUN3ME2xNE4zPDJ6IN88US=>MV3TRW5ITVJ?
NCI-H1437MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrxdopKSzVyPUGwMlU4OjVizszNM1O0ZnNCVkeHUh?=
VM-CUB-1NEnKSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrUTWM2OD1zMD62NVY1KM7:TR?=M123NHNCVkeHUh?=
A2058M3vJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXzTWM2OD1zMD62OFA1KM7:TR?=M2HjOHNCVkeHUh?=
BPH-1M4[3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTFyLkexOFUh|ryPMmG2V2FPT0WU
NB5NUP6OoEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrBT5FKSzVyPUGwMlc2PTlizszNMVrTRW5ITVJ?
G-401NH[3VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mln0TWM2OD1zMD63OlI3KM7:TR?=M2O5UHNCVkeHUh?=
CAL-72MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzhcnpZUUN3ME2xNE45ODl2IN88US=>MWfTRW5ITVJ?
SK-MEL-28MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\TUWVLUUN3ME2xNE45OjB{IN88US=>M{Sx[3NCVkeHUh?=
C32Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHLWmRnUUN3ME2xNE45OzR5IN88US=>MljTV2FPT0WU
NCI-H1155NEDjT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XDTGlEPTB;MUCuPFM4PiEQvF2=M1:5eXNCVkeHUh?=
BB49-HNCNXnYcIVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\FUXZKSzVyPUGwMlg2QDZizszNMmXDV2FPT0WU
GMS-10MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDLb3dKSzVyPUGwMlg6PzFizszNNWD0eWE5W0GQR1XS
K5NH7lRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTFyLkmwO|Eh|ryPM1vHNnNCVkeHUh?=
OS-RC-2NVrPcGg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorFTWM2OD1zMT6wOVU6KM7:TR?=M4TmRnNCVkeHUh?=
HTC-C3MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIq1e5ZKSzVyPUGxMlA4OTRizszNM1H2[3NCVkeHUh?=
LB996-RCCNGPOR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2n3e2lEPTB;MUGuNFczOyEQvF2=MkTCV2FPT0WU
NCI-H1563MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoK3TWM2OD1zMT6xNFEyKM7:TR?=M4O3dnNCVkeHUh?=
CAL-54MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{n6N2lEPTB;MUGuOFgyOSEQvF2=MXPTRW5ITVJ?
WM-115MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVSwZW9IUUN3ME2xNU43QDJ2IN88US=>M2DUXXNCVkeHUh?=
COLO-684MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTFzLkeyOlch|ryPMnnYV2FPT0WU
HOP-62MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTFzLke1NFgh|ryPMWjTRW5ITVJ?
NCI-H650MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHDdI9KSzVyPUGxMlg6PjFizszNM3\jcHNCVkeHUh?=
TE-11M3PKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LnNGlEPTB;MUGuPVMyPSEQvF2=MYTTRW5ITVJ?
COLO-679M37hVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojSTWM2OD1zMT65OFYh|ryPNVnsUGtnW0GQR1XS
FTC-133NW\UVlFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfyTWM2OD1zMj6wNFc3KM7:TR?=MUXTRW5ITVJ?
D-283MEDNGjzN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEixdYJKSzVyPUGyMlA2PjlizszNMUHTRW5ITVJ?
SK-PN-DWM{PNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHlbllwUUN3ME2xNk4yQTB{IN88US=>M1PTW3NCVkeHUh?=
BALL-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTF{LkK2OlIh|ryPNYLIUFRyW0GQR1XS
GT3TKBMnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXoTWM2OD1zMj6zNFc1KM7:TR?=MljpV2FPT0WU
HOP-92M3nyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDPS2lKSzVyPUGyMlUzOzNizszNMWXTRW5ITVJ?
M14MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHMPJpKSzVyPUGzMlA{OzVizszNM{LaXHNCVkeHUh?=
SKG-IIIaM3L0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfRNVFPUUN3ME2xN{4xPTV2IN88US=>MUHTRW5ITVJ?
BeckerM{OzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTF|LkC1PEDPxE1?M{\jVHNCVkeHUh?=
ES5MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTF|LkGzOVYh|ryPM4TIXXNCVkeHUh?=
NCI-H2030Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfNNpZGUUN3ME2xN{4zODZ{IN88US=>NV:wNmhlW0GQR1XS
SNU-423NX3MZ5FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWe2eWh3UUN3ME2xN{4{QDFizszNNVH3e|F5W0GQR1XS
CP50-MEL-BM1uwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXuZ4RKSzVyPUGzMlYzOzJizszNM4XkVHNCVkeHUh?=
NCI-H1092MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojMTWM2OD1zMz63OFc2KM7:TR?=NFLPbFNUSU6JRWK=
8-MG-BAMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTF|Lke1NVMh|ryPMX7TRW5ITVJ?
CAL-27MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LyPWlEPTB;MUSuNFczPyEQvF2=NVP4[YFRW0GQR1XS
AGSMl;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmK1TWM2OD1zND6xN|E6KM7:TR?=MXvTRW5ITVJ?
MZ2-MELNEPXVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzaVG5KSzVyPUG0MlE1QDhizszNMlPmV2FPT0WU
BFTC-909MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIOweZlKSzVyPUG0MlUxPTVizszNM3v5bnNCVkeHUh?=
D-566MGNUPiU5plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHXVIR6UUN3ME2xOE44PzB4IN88US=>M2TtVHNCVkeHUh?=
MZ7-melNX;RW5dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDaSYdKSzVyPUG1MlExPjdizszNNFLxW|NUSU6JRWK=
TE-5NHXhdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4q3e2lEPTB;MUWuNlM{OyEQvF2=NI\LOmlUSU6JRWK=
647-VMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkj0TWM2OD1zNT6yO|A2KM7:TR?=NV7iWlFMW0GQR1XS
DMS-114NXnYW417T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33remlEPTB;MUWuN|I6OSEQvF2=MoHOV2FPT0WU
ME-180NGDNW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\ITWM2OD1zNT60O|g{KM7:TR?=MlTHV2FPT0WU
MS-1NFfxUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mme5TWM2OD1zNT61OlI{KM7:TR?=MY\TRW5ITVJ?
NUGC-3NGLOT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfKTWM2OD1zNT62NlQ2KM7:TR?=NITZSnhUSU6JRWK=
GB-1MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4raXmlEPTB;MUWuOlQ{PyEQvF2=M2[0eHNCVkeHUh?=
LOXIMVING\PPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETqOWJKSzVyPUG1Mlg6OTlizszNMVPTRW5ITVJ?
NCI-H1304NF;SR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTF3Lki5Nlgh|ryPNVLvd4xzW0GQR1XS
KURAMOCHIMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTF3Lkm3NUDPxE1?M1HYUHNCVkeHUh?=
SW1783Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2K0W2lEPTB;MU[uNFk6OyEQvF2=M2\hVXNCVkeHUh?=
EGI-1NGPnN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M124d2lEPTB;MU[uOVM3PSEQvF2=MWHTRW5ITVJ?
KGNNYDwPZFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTF4LkW1PFYh|ryPMXXTRW5ITVJ?
PANC-03-27Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTF4Lke2OlIh|ryPMmf0V2FPT0WU
RH-1NGrCO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEf0PHhKSzVyPUG2MlgzPSEQvF2=M2jyPXNCVkeHUh?=
HT-1376MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\NXWRKSzVyPUG2Mlg1PDZizszNMk\OV2FPT0WU
ZR-75-30MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3K4OWlEPTB;MU[uPVM3OSEQvF2=MmfEV2FPT0WU
TI-73MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTF4Lkm0NFgh|ryPNEXISoxUSU6JRWK=
TK10NVfPc5JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nCbmlEPTB;MUeuNFA4QSEQvF2=MlrOV2FPT0WU
SW684NEjJfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGCxZoxKSzVyPUG3MlAyPTRizszNMnfrV2FPT0WU
RPMI-8866M1\hUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTKRlVLUUN3ME2xO{4xPjl7IN88US=>NWHVV3J3W0GQR1XS
LNCaP-Clone-FGCNH6zZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\jPYlKSzVyPUG3MlUzODFizszNNUn1fol[W0GQR1XS
NCI-H2291M{Lv[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjicHVKSzVyPUG4MlQ{PDVizszNNVO1[YZwW0GQR1XS
T47DM1G1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoD3TWM2OD1zOD60PFgh|ryPMXHTRW5ITVJ?
A204M2\ETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrlNFVKSzVyPUG4MlU1PTJizszNMV;TRW5ITVJ?
HT-144M2j5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTF6Lke0Nlch|ryPNWrNemVkW0GQR1XS
MDA-MB-361M4LVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fURmlEPTB;MUmuNFcyPCEQvF2=NUXP[5ZJW0GQR1XS
HCC1806MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mni4TWM2OD1zOT6xOVkyKM7:TR?=NG\TN4NUSU6JRWK=
NCI-H596M4DlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTF7Lk[zPVEh|ryPMonFV2FPT0WU
K-562MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HCOGlEPTB;MUmuPFkzPiEQvF2=MmfYV2FPT0WU
D-336MGNFrhNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTF7LkmzNlIh|ryPM4\QTHNCVkeHUh?=
SK-MEL-2NYjYR3lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XBcWlEPTB;MkCuNVU2QSEQvF2=NXGxR|RPW0GQR1XS
HEC-1MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mor4TWM2OD1{MD60PVc5KM7:TR?=MYrTRW5ITVJ?
EW-13M372cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXWxXY5tUUN3ME2yNE42PDR|IN88US=>NGj5bmVUSU6JRWK=
Hs-578-TM4HFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLKTWM2OD1{MD61OVg{KM7:TR?=NHnoSlZUSU6JRWK=
SJSA-1M1\Tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zxemlEPTB;MkCuOVY5QCEQvF2=MXXTRW5ITVJ?
RCC10RGBMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrNTWM2OD1{MD62O|E6KM7:TR?=NEPESmJUSU6JRWK=
LAN-6NX;sd|g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzwbml2UUN3ME2yNU4xOzl4IN88US=>MYjTRW5ITVJ?
NCI-H1048NUDpRVg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLCR3NiUUN3ME2yNU4zOjV6IN88US=>M1fJeXNCVkeHUh?=
CW-2MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTiWXVKSzVyPUKxMlI4ODVizszNNUfXb|lsW0GQR1XS
HCC2157NV6zN|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HFfmlEPTB;MkGuN|Yh|ryPNVnrXYhMW0GQR1XS
EW-22MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlr6TWM2OD1{MT6zO|Yh|ryPNFf5cWpUSU6JRWK=
A253M1Xnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHHWZRKSzVyPUKxMlQ1QDFizszNNViyR|ZzW0GQR1XS
BE-13NVP1V|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrLXWpKSzVyPUKxMlYyOTNizszNNFvYTIhUSU6JRWK=
KINGS-1M1G1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLxTWM2OD1{MT62N|E3KM7:TR?=NEL4dWhUSU6JRWK=
ETK-1NYn1eYNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTadnVEUUN3ME2yNU45OTV{IN88US=>NI\OSppUSU6JRWK=
NCI-H2452MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnz4TWM2OD1{MT64OlQ4KM7:TR?=MUHTRW5ITVJ?
HPAF-IINIL2fmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHXTnNKSzVyPUKxMlg6OjNizszNMUHTRW5ITVJ?
D-542MGMnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV65T2RCUUN3ME2yNU46ODZ7IN88US=>NUSxco4zW0GQR1XS
NCI-H630NYey[3RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoP6TWM2OD1{Mj6wNlk3KM7:TR?=MVPTRW5ITVJ?
TGBC11TKBNVXPPXRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUO2flkxUUN3ME2yNk4xPDlizszNMl;WV2FPT0WU
BCPAPMnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\zTlZKSzVyPUKyMlYyOSEQvF2=M3zNOXNCVkeHUh?=
HLEMn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVuwWWd4UUN3ME2yNk43QTdizszNNXjLflNpW0GQR1XS
NCI-H727MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoKwTWM2OD1{Mj63N|Uh|ryPNYi3NYhyW0GQR1XS
RDM1m1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfoW5FKSzVyPUKyMlc2OThizszNNXS2fJpmW0GQR1XS
NCI-H522MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3QTWM2OD1{Mj64OFMyKM7:TR?=NIn2fYZUSU6JRWK=
CGTH-W-1M2S0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkCyTWM2OD1{Mz6wOlQyKM7:TR?=MmnoV2FPT0WU
SK-LU-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PYR2lEPTB;MkOuOFY5OyEQvF2=NILtO5hUSU6JRWK=
BB65-RCCMknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33S[2lEPTB;MkOuO|g3OyEQvF2=NVW2UZZZW0GQR1XS
HSC-3MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnHeIhKSzVyPUKzMlg2OjdizszNMXTTRW5ITVJ?
SK-MES-1NVfPPJF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTJ2LkCxOlEh|ryPNXOxeZg{W0GQR1XS
DBMnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGqzfZpKSzVyPUK0MlExOjhizszNMmfMV2FPT0WU
HO-1-N-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjZUHlKSzVyPUK0MlMxQTNizszNMXXTRW5ITVJ?
MKN1M3rVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTJ2Lk[4JO69VQ>?M2fnUnNCVkeHUh?=
MN-60NHX2SXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XwV2lEPTB;MkSuPFUyQSEQvF2=NVy5[IlkW0GQR1XS
8505CMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jJTmlEPTB;MkWuNVg1PSEQvF2=NG\Yc2VUSU6JRWK=
COLO-320-HSRNWTQbY94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTJ3LkKyNFgh|ryPMXLTRW5ITVJ?
BB30-HNCM2\JT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljLTWM2OD1{NT6yOFg{KM7:TR?=NInrT|FUSU6JRWK=
KM12MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTJ3LkW4NFch|ryPNGfSN5pUSU6JRWK=
NB13MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTJ3LkW4PVgh|ryPMlfpV2FPT0WU
HCC2998NUXPe5FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvPUmtKSzVyPUK2MlAzQDNizszNNU\JbFBEW0GQR1XS
U-118-MGMnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXOzXnY6UUN3ME2yOk4xQDB6IN88US=>MV\TRW5ITVJ?
NB10MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPNUYRKSzVyPUK2MlI{PCEQvF2=MYjTRW5ITVJ?
SK-LMS-1NVzkZYl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLGZ4dKSzVyPUK3MlA4ODRizszNNI[4c2tUSU6JRWK=
SW1573M4Xubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnkTWM2OD1{Nz6xNUDPxE1?M{XUVnNCVkeHUh?=
LB373-MEL-DNV31coloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjTTWM2OD1{Nz6xNlk1KM7:TR?=MYDTRW5ITVJ?
DK-MGNXjzWmlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rCeWlEPTB;MkeuNVgyPyEQvF2=M4fsdHNCVkeHUh?=
RMG-INFj4VHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\hbnVKSzVyPUK3MlIxOjlizszNNITRZZhUSU6JRWK=
SW1088NF\yT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUi1V4p[UUN3ME2yO{42ODR{IN88US=>M1zPe3NCVkeHUh?=
SK-OV-3NGnJe2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1WyemlEPTB;MkeuO|U6OyEQvF2=M1r4UHNCVkeHUh?=
KP-N-YNM37zRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXNfGlXUUN3ME2yO{45ODR|IN88US=>M3m1WXNCVkeHUh?=
RPMI-7951NYTyPHZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTJ6LkK0OVYh|ryPM1q4OnNCVkeHUh?=
CaR-1M1LKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LNO2lEPTB;MkiuOVU5OiEQvF2=NGq1VGdUSU6JRWK=
MKN7NHHzW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTuT3hKSzVyPUK4MlU6PjRizszNNV25XYpOW0GQR1XS
CHP-212NVTsXY16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXX2foFwUUN3ME2yPE44PDBzIN88US=>M3\hfXNCVkeHUh?=
KYSE-450M1TDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTJ6LkiwPVEh|ryPMkDvV2FPT0WU
RXF393NFzncnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHG3[FFKSzVyPUK5MlI6ODZizszNNXnBVo5IW0GQR1XS
P30-OHKMlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEe3cZJKSzVyPUK5MlMxPDhizszNM1vhTXNCVkeHUh?=
Ca9-22MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHYOJhoUUN3ME2yPU41Ojl7IN88US=>MoroV2FPT0WU
RT-112MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXBV5k1UUN3ME2yPU41PjFzIN88US=>NE[1fGhUSU6JRWK=
ES1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7GXGVvUUN3ME2yPU45PTR2IN88US=>MmL5V2FPT0WU
HCE-4NU\wSI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fmcmlEPTB;MkmuPFc5PiEQvF2=MlzMV2FPT0WU
AM-38NGXrTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojXTWM2OD1|MD6wOlA3KM7:TR?=NUHuXHJ6W0GQR1XS
AsPC-1NULic49pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXITWM2OD1|MD64NFU{KM7:TR?=MljmV2FPT0WU
TE-9MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHS5[XBKSzVyPUOwMlg4OzdizszNNVf0coZvW0GQR1XS
HuP-T4M4i4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTNyLkm2N|gh|ryPNX\Qco9xW0GQR1XS
LB2518-MELM2\STWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfaXFd6UUN3ME2zNU4xPzR2IN88US=>NFjBTI9USU6JRWK=
NCI-H1703M{XBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknJTWM2OD1|MT6wPVA2KM7:TR?=M4\mUXNCVkeHUh?=
NCI-H2228NHTwdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nDOGlEPTB;M{GuOFY2OSEQvF2=NFiyUWFUSU6JRWK=
SCC-4M1T5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LVfWlEPTB;M{GuPVE5OSEQvF2=MWjTRW5ITVJ?
KNS-81-FDNGW5dYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVSyNI17UUN3ME2zNk4xOTJ6IN88US=>M1nZT3NCVkeHUh?=
NTERA-S-cl-D1M{i2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTN{LkC3N|kh|ryPMVLTRW5ITVJ?
DaoyNX3lVmNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2i4XmlEPTB;M{KuNFg{QCEQvF2=NFzUNGJUSU6JRWK=
ES4MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjLdnNKSzVyPUOyMlM6OjJizszNMVPTRW5ITVJ?
MHH-ES-1NWm0SmJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7CVItCUUN3ME2zNk41QDd{IN88US=>NYC0eYdlW0GQR1XS
C-33-ANFT2VohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LoemlEPTB;M{KuO|czQCEQvF2=NXHNeWNYW0GQR1XS
BHYMkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTN{Lkm0PVUh|ryPMljtV2FPT0WU
Detroit562M33kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPk[JAyUUN3ME2zN{43PjV5IN88US=>NGHrS3lUSU6JRWK=
EW-1NVLaOHhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTN|LkmzNlIh|ryPNUjtR2cyW0GQR1XS
NCI-H1395M3TLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnxXYtKSzVyPUO0MlA4QTlizszNM13sNXNCVkeHUh?=
KM-H2M{TaZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLGdY9KSzVyPUO2MlQ4PDNizszNNWrz[5hUW0GQR1XS
NCI-H520MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfWRXpKSzVyPUO2Mlc2PDFizszNNGXacXRUSU6JRWK=
D-392MGMlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XONmlEPTB;M{euN|M1PCEQvF2=NYG5WnhlW0GQR1XS
NOMO-1M1;abWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\0S2hKSzVyPUO3MlgxQDlizszNMmf5V2FPT0WU
TE-6MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPK[3lKSzVyPUO4MlEzPCEQvF2=MnTRV2FPT0WU
HT-3NVPYbmhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\QW2lEPTB;M{iuOFQ{PiEQvF2=MWLTRW5ITVJ?
RPMI-8226NInQNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYixXoFwUUN3ME2zPE46PTF7IN88US=>NHHOSnZUSU6JRWK=
U251MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLSTWM2OD1|OT6wNVI1KM7:TR?=NVjLSYdRW0GQR1XS
GCTMn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTN7LkG4OVIh|ryPNYrwWmNkW0GQR1XS
A431NEi0[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PnW2lEPTB;M{muNVg6PCEQvF2=MVnTRW5ITVJ?
TE-12MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnVTWM2OD1|OT6yOFQ5KM7:TR?=MX;TRW5ITVJ?
HMV-IINHjpTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYT0WHBFUUN3ME2zPU42ODR5IN88US=>MVvTRW5ITVJ?
IST-MES1MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3HN|lmUUN3ME20NE4yPTB{IN88US=>Ml\4V2FPT0WU
SW13NE\4[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HmbmlEPTB;NECuOVE6KM7:TR?=M3vweXNCVkeHUh?=
SF295NX7z[lVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHBTWM2OD12MD64NFY3KM7:TR?=NU\DOIVEW0GQR1XS
MDA-MB-157Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fXWGlEPTB;NECuPVQ3OiEQvF2=NULac4FtW0GQR1XS
TE-1NV7vO3ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLHPZNOUUN3ME20NU45PzF2IN88US=>MmDqV2FPT0WU
HuCCT1M3zUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvGRmNKSzVyPUSyMlUzQDlizszNMVLTRW5ITVJ?
KYSE-510MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTR|LkG3OVQh|ryPMlrWV2FPT0WU
NCI-H358M{S1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTR2LkCzNFQh|ryPM{XVVHNCVkeHUh?=
SW900NWX1WWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTGPFlNUUN3ME20OE4xPzV6IN88US=>MVHTRW5ITVJ?
CAS-1M{\GSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTR2LkC5PVEh|ryPM{nYUHNCVkeHUh?=
TE-8NGrze2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLsUZRKSzVyPUS0MlU3PThizszNNFPT[HBUSU6JRWK=
P12-ICHIKAWANV3xXmlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTR2Lk[xNVIh|ryPNXOwR4Z4W0GQR1XS
YKG-1M3nNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTR2Lke4NUDPxE1?NGfJd|dUSU6JRWK=
SNU-C2BMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofKTWM2OD12ND63PVA{KM7:TR?=NY\rN2M6W0GQR1XS
LCLC-103HMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnYfZhvUUN3ME20OE45PzB|IN88US=>NWXX[JVEW0GQR1XS
U-87-MGMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIL3TZpKSzVyPUS1MlExOjJizszNM2jBcXNCVkeHUh?=
HAL-01MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjOTWM2OD12NT6xN|c6KM7:TR?=NWPlNpdpW0GQR1XS
OVCAR-8MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYT5S3NRUUN3ME20OU4{PTZ2IN88US=>NVHn[lMzW0GQR1XS
KYSE-150M3vYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2Cx[mlEPTB;NEeuNVA2OiEQvF2=MUHTRW5ITVJ?
OE33Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYm4XGh[UUN3ME20O{4yPDJ7IN88US=>M4TlfnNCVkeHUh?=
CAL-62M4LBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmP3TWM2OD12Nz60NFY5KM7:TR?=NV\ROYFlW0GQR1XS
TCCSUPNETXcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTR5Lk[yOlQh|ryPMUjTRW5ITVJ?
H4MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NED5N|lKSzVyPUS3MlY3OjFizszNMl7VV2FPT0WU
CP66-MELMkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHPTWM2OD12OD6wO|A1KM7:TR?=MXnTRW5ITVJ?
SNB75NVnoUnIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkntTWM2OD12OD6xPFc1KM7:TR?=Mm\5V2FPT0WU
Mo-TMmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4[1fmlEPTB;NEiuNlc6KM7:TR?=Mnz0V2FPT0WU
BT-549MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkT5TWM2OD12OD6zO|I6KM7:TR?=M1jETHNCVkeHUh?=
IGR-1M{HrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXofGFXUUN3ME20PE43PjR3IN88US=>NF\5SIpUSU6JRWK=
NCI-H1299NH7YS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGK1WGNKSzVyPUS4MlczPDhizszNNYHOb|F5W0GQR1XS
ALL-POM{\1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HSWGlEPTB;NEmuPVI3QCEQvF2=NUm2WmFoW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. [2]
Features

Protocol(Only for Reference)

Cell Assay: [2]

Cell lines SW620, LoVo, V3-YAC and V3 cells
Concentrations 0.5 μM or 1 μM
Incubation Time 17 hours
Method The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min 137Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 105 per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

Animal Study: [2]

Animal Models Female rude mice bearing SW620 xenografts
Formulation Sterile 0.9% sodium chloride solution
Dosages 10 mg/kg
Administration Intraperitoneally administrated

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Leahy JJ, et al. Bioorg Med Chem Lett, 2004, 14(24), 6083-6087.

[2] Zhao Y, et al. Cancer Res, 2006 , 66(10), 5354-5362.

view more

Chemical Information

Download NU7441 (KU-57788) SDF
Molecular Weight (MW) 413.49
Formula

C25H19NO3S

CAS No. 503468-95-9
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 4 mg/mL warming (9.67 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4H-1-Benzopyran-4-one, 8-(4-dibenzothienyl)-2-(4-morpholinyl)-

Frequently Asked Questions

  • Question 1
    Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?

    Answer: Slight color variation due to different processing is normal and usually doesn't interfere with the function.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA-PK Products

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • NU7026

    NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

  • KU-0060648

    KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Recently Viewed Items

Tags: buy NU7441 (KU-57788) | NU7441 (KU-57788) supplier | purchase NU7441 (KU-57788) | NU7441 (KU-57788) cost | NU7441 (KU-57788) manufacturer | order NU7441 (KU-57788) | NU7441 (KU-57788) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us